Rapid response to rituximab in a pediatric liver transplant recipient with post‐transplant lymphoproliferative disease and maintenance with sirolimus monotherapy
Authors:
- Samhar I. Al‐AkashSASamhar I. Al‐Akash
- Abdulkarim S. Al MakadmaAMAbdulkarim S. Al Makadma
- Mohammad G. Al OmariMOMohammad G. Al Omari
- 21 March 2005
- journal article
- case report
- Published by Wiley in Pediatric Transplantation
- Vol. 9 (2) , 249-253
Abstract
Abstract: A 12‐yr‐old girl with end‐stage renal disease secondary to primary hyperoxaluria type I received a living related (left lateral segment) liver transplant from her brother as the first step of a staged liver and kidney transplant. Renal transplantation was planned for a later date from the same donor. Nine weeks after transplantation she developed polymorphic PTLD of the tonsils and adenoids. Initial treatment with surgical resection and withdrawal of immunosuppression was insufficient as she developed recurrence of the PTLD lesion 1 wk after surgical resection and reduction of immunsuppression. Treatment with the chimeric monoclonal anti CD20 antibody, rituximab (Mabthera®, Hoffman‐La Roche AG, Grenzach‐Whylen, Germany), resulted in quick response and complete recovery from PTLD within 2 wk, with no recurrence up to 8 months after treatment. Rejection prophylaxis was successfully achieved with Sirolimus (Rapamune®, Wyeth Pharmaceuticals Inc., Philadelphia, PA, USA) monotherapy, with no episodes of acute rejection.Keywords
This publication has 16 references indexed in Scilit:
- The post-transplant lymphoproliferative disorder?a literature reviewPediatric Nephrology, 2004
- Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients.Pediatric Nephrology, 2004
- Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study ReportAmerican Journal of Transplantation, 2004
- Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting dosesTransplantation, 2003
- Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainmentTransplantation, 2003
- Post-transplant lymphoproliferative disorder: a reviewBone Marrow Transplantation, 2003
- Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipientsTransplantation, 2002
- LYMPHOPROLIFERATIVE DISORDERS AFTER ORGAN TRANSPLANTATION IN CHILDRENTransplantation, 1999
- Epstein-Barr Virus Infections in Children After Transplantation of the Small IntestineAmerican Journal of Surgical Pathology, 1998
- REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPYThe Lancet, 1984